

# Agile Therapeutics First Quarter 2022 Earnings Call

May 12, 2022

# Forward-Looking Statements

Certain information contained in this presentation and other matters discussed today or answers that may be given in response to questions may include “forward-looking statements.” We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Our forward-looking statements are based on current beliefs and expectations of our management team that involve risks, potential changes in circumstances, assumptions, and uncertainties, including statements regarding our ongoing and planned manufacturing and commercialization of Twirla®, the potential market acceptance and uptake of Twirla®, our results of operations, financial condition, liquidity, prospects, growth and strategies, the length of time that we will be able to continue to fund our operating expenses and capital expenditures and our expected financing needs and sources of financing. Any or all of the forward-looking statements may turn out to be wrong or be affected by inaccurate assumptions we might make or by known or unknown risks and uncertainties. These forward-looking statements are subject to risks and uncertainties including risks related to our ability to maintain regulatory approval of Twirla, the ability of Corium to produce commercial supply in quantities and quality sufficient to satisfy market demand for Twirla, our ability to successfully commercialize Twirla, the accuracy of our estimates of the potential market for Twirla, regulatory and legislative developments in the United States and foreign countries, our ability to obtain and maintain intellectual property protection for Twirla, our strategy, business plans and focus, the effects of the COVID-19 pandemic on our operations and the operations of third parties we rely upon as well as on our potential customer base, our ability to maintain compliance with the listing requirements of the Nasdaq Capital Market, and the other risks set forth in our filings with the U.S. Securities and Exchange Commission, including our Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q. These factors could cause actual results and developments to be materially different from those expressed in or implied by such statements. These forward-looking statements are made only as of the date of this presentation and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

# Update on Financials & Financing Plan


# Update on Financing Plan

## *Company Financing Plan:*

- 1. Work Down Debt Facility with Perceptive Advisors**
- 2. Regain Compliance with Nasdaq Listing Requirements**
- 3. Raise Additional Capital**

# Update on Twirla Business Plan

# Twirla Growth Based on Key Performance Metrics (Quarterly)



Cycles Dispensed Reflects All Channels as Reported by Symphony Metys  
TRx, NRx, and RRx Reflect Retail-Only Data as Reported by Symphony Metys

# Twirla Business Plan Designed to Advance Growth



Afaxys Partnership




Targeted Focus on California



Twirla CTV Commercial

# Twirla Demand Metrics





# Twirla Business Plan Designed to Advance Growth



Afaxys Partnership




Targeted Focus on California



Twirla CTV Commercial

## Growing Number of Twirla Prescribers (Quarterly)



Reflects Retail-Only Data as Reported by Symphony Metys

# Q&A

# Closing Remarks